Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM - discu.eu

Reddit

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine https://www.nejm.org/doi/10.1056/nejmoa2034201 4 comments 14/1/2021 science

Linking pages

Johnson & Johnson coronavirus vaccine generates immune response, few side effects, in early trials | CNN https://www.cnn.com/2021/01/13/health/johnson-coronavirus-vaccine-early-trials/index.html 36 comments
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM http://dx.doi.org/10.1056/nejmoa2113017 24 comments
JCM | Free Full-Text | Influence of Seasonality and Public-Health Interventions on the COVID-19 Pandemic in Northern Europe https://www.mdpi.com/2077-0383/13/2/334 19 comments
The Genetic Code and Proteins of the Other Covid-19 Vaccines - Bert Hubert's writings https://berthub.eu/articles/posts/genetic-code-of-covid-19-vaccines/ 2 comments
J.&J. Vaccine May Be Less Effective Against Delta, Study Suggests - The New York Times https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html 0 comments
Let's unclog the FDA and save lives! - by Dan Elton https://danelton.substack.com/p/lets-unclog-the-fda-and-save-lives 0 comments
The very common vaccine ingredient at the center of J&J, AstraZeneca drama | Ars Technica https://arstechnica.com/science/2021/04/the-very-common-vaccine-ingredient-at-the-center-of-jj-astrazeneca-drama/ 0 comments
The very common vaccine ingredient at the center of J&J, AstraZeneca drama | Ars Technica https://arstechnica.com/?p=1756985 0 comments
Opinion | Are Covid Vaccine ‘Booster’ Shots Needed? - The New York Times https://www.nytimes.com/2021/08/09/opinion/covid-vaccine-booster-shot.html 0 comments

Linked pages

Related searches:

Search whole site: site:doi.org

Search title: Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM

See how to search.

Submit link to: